Track 03 of 9
Pharmacogenomics & Precision Medicine
CYP variants, biomarker-guided dosing, companion diagnostics.
Pharmacogenomics is finally entering routine practice, driven by CPIC guidelines, payer coverage expansion, and pre-emptive panel testing in major US health systems. WCPD 2027 will cover the high-impact actionable gene-drug pairs — DPYD before fluoropyrimidines, TPMT/NUDT15 for thiopurines, CYP2C19 for clopidogrel and SSRIs, HLA-B*57:01 for abacavir, HLA-B*15:02 for carbamazepine — and the implementation science required to embed results in the EHR. Sessions will also address ancestry diversity gaps in pharmacogenomic evidence, polygenic risk scores in drug response, and companion diagnostic co-development for targeted oncology therapies.
Focus areas
- CPIC-actionable pairs: DPYD, TPMT, CYP2C19, CYP2D6, HLA-B
- Pre-emptive panel testing and EHR clinical decision support
- Companion diagnostics: KRAS, EGFR, BRCA, MSI/dMMR, NTRK
- Ancestry diversity in pharmacogenomic reference data
- Tumor-agnostic approvals and basket trial pharmacology
- Polygenic scores for drug response and adverse events
- Pharmacogenomics in psychiatry: SSRI, antipsychotic dosing